
RealRate

PHARMACEUTICAL 2021

Aprea Therapeutics Inc. Rank 273 of 409





PHARMACEUTICAL 2021

Aprea Therapeutics Inc. Rank 273 of 409

The relative strengths and weaknesses of Aprea Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aprea Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 171% points. The greatest weakness of Aprea Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 163% points.

The company's Economic Capital Ratio, given in the ranking table, is -238%, being 116% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	92,417
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,331
Liabilities, Non-Current	79
Other Assets	350
Other Compr. Net Income	1,497
Other Expenses	0
Other Liabilities	0
Other Net Income	-668
Property and Equipment	39
Research and Development	37,879
Revenues	0
Selling, General and Administrative Expense	14,932

Output Variable	Value in 1000 USD
Assets	92,805
Liabilities	15,410
Expenses	52,811
Stockholders Equity	77,395
Net Income	-53,479
Comprehensive Net Income	-52,731
Economic Capital Ratio	-238%